Trial Profile
Phase II Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2021
Price :
$35
*
At a glance
- Drugs Canerpaturev (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms Neo-NivoHF10
- 15 Oct 2020 Status changed from active, no longer recruiting to discontinued.
- 09 Aug 2019 Planned End Date changed from 1 Sep 2023 to 1 Sep 2020.
- 02 Jul 2019 Planned End Date changed from 1 Sep 2020 to 1 Sep 2023.